No Data
No Data
China Regenerative Medicine (08158.HK): Shareholders' share loss of approximately HK$108 million in 2023
On April 2, China Regenerative Medicine (08158.HK) announced that for the year ended December 31, 2023, revenue was approximately HK$69.49 million, an increase of 67.29% over the previous year; gross profit decreased by 48.37% from the previous year to approximately HK$19.42 million; the company's equity holders should account for the current year's loss of approximately HK$108 million (2022: profit of HK$4.56 million), with a basic loss of HK$37.60 per share.
CRMI: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
China Regenerative Medicine (08158.HK) appoints Zhongzheng Tianheng as new auditor
Gelonghui, January 25 | China Regenerative Medicine (08158.HK) announced that Changying (Hong Kong) Certified Public Accountants Limited (“Changying”) submitted a letter of resignation to the board of directors to resign as the company's auditor with immediate effect. Following the recommendation of the Audit Committee, it has decided to appoint Zhongzheng Tianheng Certified Public Accountants Co., Ltd. (“Zhongzheng Tianheng”) as the company's new auditor.
China Regenerative Medicine (08158) affiliate plans to inject 10.25 million yuan into Changzhou Pomei Biotechnology
Zhitong Finance App News, China Regenerative Medicine (08158) announced that on December 29, 2023 (after the transaction period), China Regenerative Health, Changzhou Starry Sky, and the target company Changzhou Bomei Biotechnology Co., Ltd. signed a capital increase and subscription agreement. According to this, China Regenerative Health must inject RMB 10.25 million into the target company in cash, of which RMB 250,000 will be injected to increase the target company's registered capital, while RMB 10 million will be injected into its capital reserve. Upon completion, the target company will hold approximately 33.3% of China Regenerative Health's equity and Changzhou Star
CRMI: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
CRMI: Third Quarterly Report 2023
No Data